Takeda's TAK-921 improves survival in Phase 3 advanced gastric cancer trial

By Public Technologies
  • Takeda’s arcotatug tavatecan met survival endpoints in Phase 3 G-HOPE-001 in previously treated, advanced CLDN18.2-positive gastric or gastroesophageal junction cancer.
  • Median overall survival reached 10.2 months versus 6.9 months with physician-selected treatment at the September 3, 2026, cutoff (P<0.0001).
  • Median progression-free survival was 7.1 months versus 3.1 months with physician-selected treatment in the second interim analysis.
  • Grade 3 or higher treatment-related adverse events occurred in 47.4% versus 55.9%; one treatment-related death occurred with arcotatug tavatecan.
  • Results will support a planned Japanese regulatory filing; global Phase 3 trials in gastric and pancreatic cancer are planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021967745) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk